Last data update: Nov 11, 2024. (Total: 48109 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Lavilla K[original query] |
---|
Contact tracing for mpox clade II cases associated with air travel - United States, July 2021-August 2022
Delea KC , Chen TH , Lavilla K , Hercules Y , Gearhart S , Preston LE , Hughes CM , Minhaj FS , Waltenburg MA , Sunshine B , Rao AK , McCollum AM , Adams K , Ocaña M , Akinkugbe O , Brown C , Alvarado-Ramy F . MMWR Morb Mortal Wkly Rep 2024 73 (35) 758-762 Monkeypox virus (MPXV) can spread among humans through direct contact with lesions, scabs, or saliva; via respiratory secretions; and indirectly from fomites; via percutaneous injuries; and by crossing the placenta to the fetus during pregnancy. Since 2022, most patients with mpox in the United States have experienced painful skin lesions, and some have had severe illness. During 2021-2022, CDC initiated aircraft contact investigations after receiving reports of travelers on commercial flights with probable or confirmed mpox during their infectious period. Data were collected 1) during 2021, when two isolated clade II mpox cases not linked to an outbreak were imported into the United States by international travelers and 2) for flights arriving in or traveling within the United States during April 30-August 2, 2022, after a global clade II mpox outbreak was detected in May 2022. A total of 113 persons (100 passengers and 13 crew members) traveled on 221 flights while they were infectious with mpox. CDC developed definitions for aircraft contacts based on proximity to mpox cases and flight duration, sent information about these contacts to U.S. health departments, and received outcome information for 1,046 (68%) of 1,538 contacts. No traveler was found to have acquired mpox via a U.S. flight exposure. For persons with mpox and their contacts who had departed from the United States, CDC forwarded contact information as well as details about the exposure event to destination countries to facilitate their own public health investigations. Findings from these aircraft contact investigations suggest that traveling on a flight with a person with mpox does not appear to constitute an exposure risk or warrant routine contact tracing activities. Nonetheless, CDC recommends that persons with mpox isolate and delay travel until they are no longer infectious. |
On alert for Ebola: public health risk assessment of travellers from Uganda to the U.S. during the 2022 outbreak
Fowler JJ , Preston LE , Gearhart SL , Figueroa A , LChristensen D , Mitchell C , Hernandez E , Grills AW , Morrison SM , Wilkinson M , Talib T , Marie Lavilla K , Watson T , Mitcham D , Nash R , Veguilla MAC , Hansen S , Cohen NJ , Nu Clarke SA , Smithson A , Shearer E , Pella DG , Morris JD , Meehan S , Aboukheir M , Adams K , Sunavala Z , Conley J , Abouattier M , Palo M , Pimentel LC , Berro A , Mainzer H , Byrkit R , Kim D , Katebi V , Alvarado-Ramy F , Roohi S , Wojno AE , Brown CM , Gertz AM . J Travel Med 2024 31 (5) BACKGROUND: On 20 September 2022, the Ugandan Ministry of Health declared an outbreak of Ebola disease caused by Sudan ebolavirus. METHODS: From 6 October 2022 to 10 January 2023, Centers for Disease Control and Prevention (CDC) staff conducted public health assessments at five US ports of entry for travellers identified as having been in Uganda in the past 21 days. CDC also recommended that state, local and territorial health departments ('health departments') conduct post-arrival monitoring of these travellers. CDC provided traveller contact information, daily to 58 health departments, and collected health department data regarding monitoring outcomes. RESULTS: Among 11 583 travellers screened, 132 (1%) required additional assessment due to potential exposures or symptoms of concern. Fifty-three (91%) health departments reported receiving traveller data from CDC for 10 114 (87%) travellers, of whom 8499 (84%) were contacted for monitoring, 1547 (15%) could not be contacted and 68 (1%) had no reported outcomes. No travellers with high-risk exposures or Ebola disease were identified. CONCLUSION: Entry risk assessment and post-arrival monitoring of travellers are resource-intensive activities that had low demonstrated yield during this and previous outbreaks. The efficiency of future responses could be improved by incorporating an assessment of risk of importation of disease, accounting for individual travellers' potential for exposure, and expanded use of methods that reduce burden to federal agencies, health departments, and travellers. |
Status of HIV epidemic control among adolescent girls and young women aged 15-24 years - seven African countries, 2015-2017
Brown K , Williams DB , Kinchen S , Saito S , Radin E , Patel H , Low A , Delgado S , Mugurungi O , Musuka G , Tippett Barr BA , Nwankwo-Igomu EA , Ruangtragool L , Hakim AJ , Kalua T , Nyirenda R , Chipungu G , Auld A , Kim E , Payne D , Wadonda-Kabondo N , West C , Brennan E , Deutsch B , Worku A , Jonnalagadda S , Mulenga LB , Dzekedzeke K , Barradas DT , Cai H , Gupta S , Kamocha S , Riggs MA , Sachathep K , Kirungi W , Musinguzi J , Opio A , Biraro S , Bancroft E , Galbraith J , Kiyingi H , Farahani M , Hladik W , Nyangoma E , Ginindza C , Masangane Z , Mhlanga F , Mnisi Z , Munyaradzi P , Zwane A , Burke S , Kayigamba FB , Nuwagaba-Biribonwoha H , Sahabo R , Ao TT , Draghi C , Ryan C , Philip NM , Mosha F , Mulokozi A , Ntigiti P , Ramadhani AA , Somi GR , Makafu C , Mugisha V , Zelothe J , Lavilla K , Lowrance DW , Mdodo R , Gummerson E , Stupp P , Thin K , Frederix K , Davia S , Schwitters AM , McCracken SD , Duong YT , Hoos D , Parekh B , Justman JE , Voetsch AC . MMWR Morb Mortal Wkly Rep 2018 67 (1) 29-32 In 2016, an estimated 1.5 million females aged 15-24 years were living with human immunodeficiency virus (HIV) infection in Eastern and Southern Africa, where the prevalence of HIV infection among adolescent girls and young women (3.4%) is more than double that for males in the same age range (1.6%) (1). Progress was assessed toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 2020 targets for adolescent girls and young women in sub-Saharan Africa (90% of those with HIV infection aware of their status, 90% of HIV-infected persons aware of their status on antiretroviral treatment [ART], and 90% of those on treatment virally suppressed [HIV viral load <1,000 HIV RNA copies/mL]) (2) using data from recent Population-based HIV Impact Assessment (PHIA) surveys in seven countries. The national prevalence of HIV infection in adolescent girls and young women aged 15-24 years, the percentage who were aware of their status, and among those persons who were aware, the percentage who had achieved viral suppression were calculated. The target for viral suppression among all persons with HIV infection is 73% (the product of 90% x 90% x 90%). Among all seven countries, the prevalence of HIV infection among adolescent girls and young women was 3.6%; among those in this group, 46.3% reported being aware of their HIV-positive status, and 45.0% were virally suppressed. Sustained efforts by national HIV and public health programs to diagnose HIV infection in adolescent girls and young women as early as possible to ensure rapid initiation of ART should help achieve epidemic control among adolescent girls and young women. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Nov 11, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure